Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,820 Mln
Revenue (TTM)
$331 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
3.3
Industry P/E
--
EV/EBITDA
30.9
Div. Yield
0 %
Debt to Equity
0.4
Book Value
$--
EPS
$-0.4
Face value
--
Shares outstanding
113,684,064
CFO
$-196.86 Mln
EBITDA
$-262.92 Mln
Net Profit
$-443.71 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Dynavax Technologies (DVAX)
| 0.8 | 0.6 | 43.1 | 17.9 | 12.1 | 7.9 | -1.6 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Dynavax Technologies (DVAX)
| 20.4 | -8.6 | 31.4 | -24.4 | 216.2 | -22.2 | -37.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Dynavax Technologies (DVAX)
|
15.5 | 1,820.1 | 330.5 | -43.4 | -10.3 | -8.1 | -- | 3.3 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 229.3 | 13,405.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 14.6 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of... infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California. Address: 2100 Powell Street, EmeryVille, CA, United States, 94608 Read more
CEO, Interim CFO & Director
Mr. Ryan Spencer
CEO & Director
Mr. Ryan Spencer
Headquarters
EmeryVille, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Dynavax Technologies Corporation (DVAX) is $15.50 (NASDAQ) as of 10-Feb-2026 16:00 EDT. Dynavax Technologies Corporation (DVAX) has given a return of 12.11% in the last 3 years.
Since, TTM earnings of Dynavax Technologies Corporation (DVAX) is negative, P/E ratio is not available.
The P/B ratio of Dynavax Technologies Corporation (DVAX) is 3.30 times as on 10-Feb-2026, a 16 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
71.55
|
3.27
|
|
2023
|
-291.63
|
3.00
|
|
2022
|
5.51
|
2.78
|
|
2021
|
22.92
|
7.91
|
|
2020
|
-6.52
|
8.36
|
The 52-week high and low of Dynavax Technologies Corporation (DVAX) are Rs 15.73 and Rs 9.20 as of 04-Apr-2026.
Dynavax Technologies Corporation (DVAX) has a market capitalisation of $ 1,820 Mln as on 10-Feb-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Dynavax Technologies Corporation (DVAX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.